News

Among patients with ovarian cancer who received first-line treatment with bevacizumab, clinical outcomes and tolerability are consistent in the real-world setting and clinical trials.

Findings from a real-world study suggest the addition of pertuzumab to trastuzumab and chemotherapy improves safety and OS for patients with metastatic breast cancer.

Study findings show breast cancer episodes in older women with distant metastases frequently exceeded the target price under the OCM payment methodology.

A review published in Therapeutic Advances in Hematology summarized the treatment landscape of newly diagnosed and relapsed and refractory MCL.

Real-world evidence from US community-based oncology practices supports the adoption of bevacizumab-awwb for treating patients with metastatic colorectal cancer.

Findings from a qualitative study at the Mayo Clinic suggest that patients with ovarian cancer are willing to adhere to oral olaparib therapy long term.

Findings from a recent study suggest that patients with CLL with atrial fibrillation may be at a significantly increased risk of all-cause mortality, cardiac-related mortality, and stroke.

Study findings show that trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.

Study findings report no clinically meaningful differences in febrile neutropenia incidence, HCRU, or costs between on-body injector and prefilled syringe methods of pegfilgrastim administration.

Patients with platinum-sensitive, recurrent ovarian cancer whose disease progressed following olaparib maintenance experienced poor response to subsequent platinum-based chemotherapy, according to a recent study.